Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Multiple Myeloma 1Metastatic Hormone Refractory Prostate Cancer 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × danusertib × Clear all
NCT00766324 2014-05-28

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Nerviano Medical Sciences

Phase 2 Completed
118 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00872300 2014-05-28

PHA-739358 for the Treatment of Multiple Myeloma

Nerviano Medical Sciences

Phase 2 Terminated
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡